| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Anatomy and Cell Biology, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, Iowa 52242
2 Department of Internal Medicine, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, Iowa 52242
3 Department of Neurology, University of Iowa Roy J. and Lucille A. Carver College of Medicine, Iowa City, Iowa 52242
The Cre/loxP system has shown promise for investigating genes involved in nervous system function and pathology, although its application for studying central neural regulation of cardiovascular function and disease has not been explored. Here, we report for the first time that recombination of loxP-flanked genes can be achieved in discrete cardiovascular regulatory nuclei of adult mouse brain using targeted delivery of adenovirus (Ad) or feline immunodeficiency virus (FIV) bearing Cre recombinase (Ad-Cre, FIV-Cre). Single stereotaxic microinjections of Ad-Cre or FIV-Cre into specific nuclei along the subfornical organ-hypothalamic-hypophysial and brain stem-parabrachial axes resulted in robust and highly localized gene deletion as early as 7 days and for as long as 3 wk in a reporter mouse model in which Cre recombinase activates ß-galactosidase expression. An even greater selectivity in Cre-mediated gene deletion could be achieved in unique subpopulations of cells, such as vasopressin-synthesizing magnocellular neurons, by delivering Ad-Cre via retrograde transport. Moreover, Ad-Cre and FIV-Cre induced gene recombination in differential cell populations within these cardiovascular nuclei. FIV-Cre infection resulted in LacZ activation selectively in neurons, whereas both neuronal and glial cell types underwent gene recombination upon infection with Ad-Cre. These results establish the feasibility of using a combination of viral and Cre/loxP technologies to target specific cardiovascular nuclei in the brain for conditional gene modification and suggest the potential of this approach for determining the functional role of genes within these sites.
adenovirus; feline immunodeficiency virus; renin-angiotensin system; central nervous system; gene therapy; blood pressure; hypertension
This article has been cited by other articles:
|
|
 |
|
  J. R. Peterson, M. A. Burmeister, X. Tian, Y. Zhou, M. R. Guruju, J. A. Stupinski, R. V. Sharma, and R. L. Davisson Genetic Silencing of Nox2 and Nox4 Reveals Differential Roles of These NADPH Oxidase Homologues in the Vasopressor and Dipsogenic Effects of Brain Angiotensin II Hypertension, November 1, 2009; 54(5): 1106 - 1114. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. E. Lindley, D. W. Infanger, M. Rishniw, Y. Zhou, M. F. Doobay, R. V. Sharma, and R. L. Davisson Scavenging superoxide selectively in mouse forebrain is associated with improved cardiac function and survival following myocardial infarction Am J Physiol Regulatory Integrative Comp Physiol, January 1, 2009; 296(1): R1 - R8. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. L. Grobe, D. Xu, and C. D. Sigmund An Intracellular Renin-Angiotensin System in Neurons: Fact, Hypothesis, or Fantasy Physiology, August 1, 2008; 23(4): 187 - 193. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. J. Ho, C. E. Bass, A. H. K. Kroemer, C. Ma, E. Terwilliger, and S. J. Karp Optimized adeno-associated virus 8 produces hepatocyte-specific Cre-mediated recombination without toxicity or affecting liver regeneration Am J Physiol Gastrointest Liver Physiol, August 1, 2008; 295(2): G412 - G419. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Z. Lin, Y. Chen, W. Zhang, A. F. Chen, S. Lin, and M. Morris RNA interference shows interactions between mouse brainstem angiotensin AT1 receptors and angiotensin-converting enzyme 2 Exp Physiol, May 1, 2008; 93(5): 676 - 684. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. R. Peterson, D. W. Infanger, V. A. Braga, Y. Zhang, R. V. Sharma, J. F. Engelhardt, and R. L. Davisson Longitudinal noninvasive monitoring of transcription factor activation in cardiovascular regulatory nuclei using bioluminescence imaging Physiol Genomics, April 1, 2008; 33(2): 292 - 299. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Feng, X. Yue, H. Xia, S. M. Bindom, P. J. Hickman, C. M. Filipeanu, G. Wu, and E. Lazartigues Angiotensin-Converting Enzyme 2 Overexpression in the Subfornical Organ Prevents the Angiotensin II-Mediated Pressor and Drinking Responses and Is Associated With Angiotensin II Type 1 Receptor Downregulation Circ. Res., March 28, 2008; 102(6): 729 - 736. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. D. Sigmund and R. L. Davisson Targeting Brain AT1 Receptors By RNA Interference Hypertension, February 1, 2006; 47(2): 145 - 146. [Full Text] [PDF]
|
|
|
|
|
|
T. Lonergan, A. G. Teschemacher, D. Y. Hwang, K.-S. Kim, A. E. Pickering, and S. Kasparov Targeting brain stem centers of cardiovascular control using adenoviral vectors: impact of promoters on transgene expression Physiol Genomics, January 20, 2005; 20(2): 165 - 172. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. I. Phillips A Cre-loxP solution for defining the brain renin-angiotensin system. Focus on "Targeted viral delivery of Cre recombinase induces conditional gene deletion in cardiovascular circuits of the mouse brain" Physiol Genomics, June 17, 2004; 18(1): 1 - 3. [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |
